Stockholm - Delayed Quote SEK

Egetis Therapeutics AB (publ) (EGTX.ST)

Compare
6.59 +0.15 (+2.33%)
At close: December 20 at 5:29:32 PM GMT+1
Loading Chart for EGTX.ST
DELL
  • Previous Close 6.44
  • Open 6.43
  • Bid 6.51 x --
  • Ask 6.57 x --
  • Day's Range 6.25 - 6.59
  • 52 Week Range 4.04 - 9.30
  • Volume 580,135
  • Avg. Volume 649,615
  • Market Cap (intraday) 2.367B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -1.10
  • Earnings Date Feb 20, 2025 - Feb 24, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 11.50

Egetis Therapeutics AB (publ), a pharmaceutical company, focuses on projects in late-stage development for the treatment of serious diseases with unmet medical needs in the orphan drug segment. Its products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of MCT8 deficiency, a highly debilitating rare disease with no available treatment. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is based in Stockholm, Sweden.

www.egetis.com

28

Full Time Employees

December 31

Fiscal Year Ends

Recent News: EGTX.ST

View More

Performance Overview: EGTX.ST

Trailing total returns as of 12/20/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

EGTX.ST
18.10%
OMX Stockholm 30 Index
3.19%

1-Year Return

EGTX.ST
8.93%
OMX Stockholm 30 Index
3.78%

3-Year Return

EGTX.ST
3.94%
OMX Stockholm 30 Index
7.32%

5-Year Return

EGTX.ST
62.24%
OMX Stockholm 30 Index
38.77%

Compare To: EGTX.ST

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: EGTX.ST

View More

Valuation Measures

Annual
As of 12/20/2024
  • Market Cap

    2.37B

  • Enterprise Value

    2.35B

  • Trailing P/E

    --

  • Forward P/E

    8.78

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    28.73

  • Price/Book (mrq)

    7.43

  • Enterprise Value/Revenue

    34.59

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -34.10%

  • Return on Equity (ttm)

    -81.32%

  • Revenue (ttm)

    68M

  • Net Income Avi to Common (ttm)

    -319.4M

  • Diluted EPS (ttm)

    -1.10

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    129.9M

  • Total Debt/Equity (mrq)

    34.90%

  • Levered Free Cash Flow (ttm)

    -120.72M

Research Analysis: EGTX.ST

View More

Company Insights: EGTX.ST

Research Reports: EGTX.ST

View More

People Also Watch